



HUTCHISON CHINA MEDITECH LTD

Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)

Appointment of Senior Independent Director

London, 29 September 2006: Chi-Med today announces that it has appointed Mr. Christopher Nash, an Independent Non-executive Director of Chi-Med since the admission of trading of its shares on AIM in May this year, as its Senior Independent Director.

Ends

Enquiries

Chi-Med Telephone: +852-2121-8200

Christian Hogg, CEO

Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571

Anthony Carlisle (07973 611 888)

Chris Gardner (07903 737 649)

Yvonne Alexander (07866 610 682)

Notes to Editors

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients. Its overall aim is to draw on the untapped wealth of knowledge and history of usage in the Traditional Chinese Medicine industry to develop products for the global market. The Company has three complementary businesses: drug R&D, China healthcare and consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.